<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value"/></p>
<p>纳斯达克：IRWD 1 年股价与公允价值对比</p>
<p>探索来自社区的 Ironwood Pharmaceuticals 公允价值并选择您的观点</p>
<p>上周，Ironwood Pharmaceuticals, Inc.（纳斯达克：IRWD）的股票上涨了 15%，但在过去一年中出售了价值 51.5 万美元股票的内部人士可能处于更有利的位置。以每股 1.78 美元的平均价格出售，超过当前价格，可能是明智的选择，因为持有股票意味着他们的投资现在的价值低于出售时的价值。</p>
<p>虽然我们绝不会建议投资者仅仅根据公司董事的行为来做出决策，但逻辑上你应该关注内部人士是否在买入或卖出股票。</p>
<p>特朗普承诺要 “释放” 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<h2>Ironwood Pharmaceuticals 过去 12 个月的内部交易</h2>
<p>在过去一年中，我们看到最大的内部出售是首席执行官兼董事 Thomas McCourt 以约 245,000 美元的股份出售，价格约为每股 1.76 美元。我们通常不喜欢看到内部人士出售，但出售价格越低，我们越担心。好的一面是，这次出售发生在最新价格（1.03 美元）之上。因此，很难从中得出任何强有力的结论。</p>
<p>Ironwood Pharmaceuticals 的内部人士在过去一年中没有购买任何股票。您可以在下面的图表中看到过去一年内部交易（由公司和个人进行）的情况。点击下面的图表，您可以查看每笔内部交易的详细信息！</p>
<p>查看我们对 Ironwood Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239"/></p>
<p>纳斯达克：IRWD 内部交易量 2025 年 8 月 17 日</p>
<p>如果您和我一样，那么您 <strong>不</strong> 会想错过这份 <strong>免费的</strong> 小型股名单，这些股票不仅被内部人士购买，而且估值也很有吸引力。</p>
<h2>Ironwood Pharmaceuticals 的内部人士最近出售了股票</h2>
<p>在过去三个月中，我们看到 Ironwood Pharmaceuticals 有一些内部人士出售股票。在此期间，内部人士仅出售了价值 11,000 美元的股份。看到内部人士出售股票以及缺乏近期买家的情况并不好。但出售的规模并不足以作为有用的信号。</p>
<h2>Ironwood Pharmaceuticals 是否拥有高比例的内部持股？</h2>
<p>查看公司内部人士的总持股可以帮助您了解他们是否与普通股东的利益一致。高比例的内部持股通常使公司领导层更加关注股东的利益。从我们的数据来看，内部人士持有价值 400 万美元的 Ironwood Pharmaceuticals 股票，约占公司 2.4%。我们更倾向于看到高比例的内部持股。</p>
<h2>Ironwood Pharmaceuticals 的内部交易可能告诉我们什么？</h2>
<p>在过去三个月中，我们没有看到任何内部人士买入，但我们确实看到了出售。但出售规模较小，因此我们并不担心。我们对 Ironwood Pharmaceuticals 的内部出售持谨慎态度。根据我们的数据，通常内部人士在公司中拥有更多股票。因此，这些内部交易可以帮助我们建立对该股票的看法，但了解该公司面临的风险也是值得的。每家公司都有风险，我们已经发现了 <strong>3 个警告信号</strong>，您应该了解 Ironwood Pharmaceuticals。</p>
<p>当然，<strong>您可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请查看这份 <strong>免费的</strong> 有趣公司名单。</p>
<p><em>在本文中，内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。</em></p>

Ironwood医药

<p>Ironwood Pharma（NASDAQ:IRWD）上周股价上涨了 15%，但内部人士在过去一年内出售了价值 51.5 万美元的股票，其中首席执行官 Thomas McCourt 的最大出售额为 24.5 万美元。尽管有出售，但平均出售价格高于当前价格 1.03 美元。内部人士持有公司约 2.4% 的股份，尽管有一些出售，但并不足以引发重大担忧。投资者应保持谨慎，并考虑与公司相关的风险</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value"/></p>
<p>NasdaqGS:IRWD 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>纳斯达克：IRWD 1 年股价与公允价值对比</p>
</div><p>Explore Ironwood Pharmaceuticals's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索来自社区的 Ironwood Pharmaceuticals 公允价值并选择您的观点</p>
</div><p>Last week, Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) stock jumped 15%, but insiders who sold US$515k worth of stock in over the past year are likely to be in a better position. Selling at an average price of US$1.78, which is higher than the current price might have been the right call as holding on to stock would have meant their investment would be worth less now than it was at the time of sale.</p>
<div class="lb-trans"><p>上周，Ironwood Pharmaceuticals, Inc.（纳斯达克：IRWD）的股票上涨了 15%，但在过去一年中出售了价值 51.5 万美元股票的内部人士可能处于更有利的位置。以每股 1.78 美元的平均价格出售，超过当前价格，可能是明智的选择，因为持有股票意味着他们的投资现在的价值低于出售时的价值。</p>
</div><p>While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.</p>
<div class="lb-trans"><p>虽然我们绝不会建议投资者仅仅根据公司董事的行为来做出决策，但逻辑上你应该关注内部人士是否在买入或卖出股票。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要 “释放” 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><h2>The Last 12 Months Of Insider Transactions At Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 过去 12 个月的内部交易</h2>
</div><p>Over the last year, we can see that the biggest insider sale was by the CEO &amp; Director, Thomas McCourt, for US$245k worth of shares, at about US$1.76 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$1.03). So it is hard to draw any strong conclusion from it.</p>
<div class="lb-trans"><p>在过去一年中，我们看到最大的内部出售是首席执行官兼董事 Thomas McCourt 以约 245,000 美元的股份出售，价格约为每股 1.76 美元。我们通常不喜欢看到内部人士出售，但出售价格越低，我们越担心。好的一面是，这次出售发生在最新价格（1.03 美元）之上。因此，很难从中得出任何强有力的结论。</p>
</div><p>Ironwood Pharmaceuticals insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals 的内部人士在过去一年中没有购买任何股票。您可以在下面的图表中看到过去一年内部交易（由公司和个人进行）的情况。点击下面的图表，您可以查看每笔内部交易的详细信息！</p>
</div><p>Check out our latest analysis for Ironwood Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 Ironwood Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239" alt="" original-src="https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239"/></p>
<p>NasdaqGS:IRWD Insider Trading Volume August 17th 2025</p>
<div class="lb-trans"><p>纳斯达克：IRWD 内部交易量 2025 年 8 月 17 日</p>
</div><p>If you are like me, then you will <strong>not</strong> want to miss this <strong>free</strong> list of small cap stocks that are not only being bought by insiders but also have attractive valuations.</p>
<div class="lb-trans"><p>如果您和我一样，那么您 <strong>不</strong> 会想错过这份 <strong>免费的</strong> 小型股名单，这些股票不仅被内部人士购买，而且估值也很有吸引力。</p>
</div><h2>Insiders At Ironwood Pharmaceuticals Have Sold Stock Recently</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 的内部人士最近出售了股票</h2>
</div><p>We have seen a bit of insider selling at Ironwood Pharmaceuticals, over the last three months. Insiders sold just US$11k worth of shares in that time. It's not great to see insider selling, nor the lack of recent buyers. But the selling simply isn't sufficiently substantial to be of much use as a signal.</p>
<div class="lb-trans"><p>在过去三个月中，我们看到 Ironwood Pharmaceuticals 有一些内部人士出售股票。在此期间，内部人士仅出售了价值 11,000 美元的股份。看到内部人士出售股票以及缺乏近期买家的情况并不好。但出售的规模并不足以作为有用的信号。</p>
</div><h2>Does Ironwood Pharmaceuticals Boast High Insider Ownership?</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 是否拥有高比例的内部持股？</h2>
</div><p>Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$4.0m worth of Ironwood Pharmaceuticals stock, about 2.4% of the company. We prefer to see high levels of insider ownership.</p>
<div class="lb-trans"><p>查看公司内部人士的总持股可以帮助您了解他们是否与普通股东的利益一致。高比例的内部持股通常使公司领导层更加关注股东的利益。从我们的数据来看，内部人士持有价值 400 万美元的 Ironwood Pharmaceuticals 股票，约占公司 2.4%。我们更倾向于看到高比例的内部持股。</p>
</div><h2>What Might The Insider Transactions At Ironwood Pharmaceuticals Tell Us?</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 的内部交易可能告诉我们什么？</h2>
</div><p>We did not see any insider buying in the last three months, but we did see selling. But the sales were small, so we're not concerned. We're a little cautious about the insider selling at Ironwood Pharmaceuticals. And usually insiders own more stock in the company, according to our data. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted <strong>3 warning signs for Ironwood Pharmaceuticals</strong> you should know about.</p>
<div class="lb-trans"><p>在过去三个月中，我们没有看到任何内部人士买入，但我们确实看到了出售。但出售规模较小，因此我们并不担心。我们对 Ironwood Pharmaceuticals 的内部出售持谨慎态度。根据我们的数据，通常内部人士在公司中拥有更多股票。因此，这些内部交易可以帮助我们建立对该股票的看法，但了解该公司面临的风险也是值得的。每家公司都有风险，我们已经发现了 <strong>3 个警告信号</strong>，您应该了解 Ironwood Pharmaceuticals。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of interesting companies.</p>
<div class="lb-trans"><p>当然，<strong>您可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请查看这份 <strong>免费的</strong> 有趣公司名单。</p>
</div><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p>
<div class="lb-trans"><p><em>在本文中，内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。</em></p>
</div>

随着内部人士出售股票金额达到 51.5 万美元，需密切关注 Ironwood Pharmaceuticals